Markets
The
@themarke...
Bought RXRX
Shares
down -0.99%
At 6.04, Now 5.98
Just threw some money into RXRX at its 52-week all-time low. I believe this AI biotech stock has potential for growth, especially if the AI wave conti...
Read
More
Thesis
Just threw some money into RXRX at its 52-week all-time low. I believe this AI biotech stock has potential for growth, especially if the AI wave continues. It seems like a solid investment opportunity for the next few months.
Go back
TLAMB91
@tlamb91
Bought RXRX
Shares
down -4.93%
At 6.29, Now 5.98
being loaded again in this prior gap fill support area
Thesis
being loaded again in this prior gap fill support area
Go back
Degenerate
@wsb
Bought RXRX
Shares
up 1.21%
At 6.6, Exited 6.68
I just bought RXRX at $6.70 because I see a lot of institutional buying, including Blackrock and State Street. The short interest is significant, and ...
Read
More
Thesis
I just bought RXRX at $6.70 because I see a lot of institutional buying, including Blackrock and State Street. The short interest is significant, and I believe the current valuation makes it a great medium-term investment opportunity.
Go back
Tendies
@tendies
Bought RXRX
Shares
down -2.07%
At 6.75, Exited 6.61
I believe RXRX has significant potential due to Nvidia's substantial investment, which could drive the stock price up in the coming months. Despite th...
Read
More
Thesis
I believe RXRX has significant potential due to Nvidia's substantial investment, which could drive the stock price up in the coming months. Despite the bad financials, the backing from a tech giant like Nvidia makes me think there's an opportunity for a solid swing trade.
Go back
The
@themarke...
Bought RXRX
Shares
down -8.52%
At 6.75, Exited 6.17
Recursion Pharmaceuticals has a strong pipeline and strategic AI-driven acquisitions, setting it up for significant growth. The company’s robust finan...
Read
More
Thesis
Recursion Pharmaceuticals has a strong pipeline and strategic AI-driven acquisitions, setting it up for significant growth. The company’s robust financial position and advanced drug candidates make it a compelling long-term investment opportunity.
Go back
The
@themarke...
Bought RXRX
Shares
up 2.37%
At 6.75, Exited 6.91
Recursion Pharmaceuticals is poised for significant growth with its robust drug pipeline, strong financial position, and the strategic acquisition of ...
Read
More
Thesis
Recursion Pharmaceuticals is poised for significant growth with its robust drug pipeline, strong financial position, and the strategic acquisition of Exscientia. The potential upside from its innovative R&D and AI-driven drug discovery makes RXRX a promising long-term buy.
Go back
Point72
@point72-...
Bought RXRX
Shares
down -7.86%
At 7.16, Exited 7.5
Trims & Adds
[] Lost $1.1M on the trade
[-] 144d ago
All out @
8.0
[-] 235d ago
Trimmed 1.1M shares @
9.0
[+] 326d ago
Added 1.3M shares @
10.0
[+] 1.1y ago
Initial 137.5K shares @
7.0
Thesis
Go back
